TNF and inflammatory bowel disease: Thus, we can place our findings about the specificity of the anti-TNF M2 pathway in clinical context; the outcomes of anti-TNF biologic therapy in RA and IBD in terms of enhancement of the number and function of M2 macrophages are likely variable and patient specific.